Fall Clinical Dermatology Conference

Sun Pharma presented long-term data on Leqselvi 8 mg tablets, showing significant scalp hair regrowth in severe alopecia areata patients.

Catch up on coverage from the second day of the 2024 Fall Clinical Dermatology Conference in Las Vegas, Nevada.

Shawn Kwatra, MD, reviews key highlights of his sessions at Fall Clinical 2024 on the latest updates in itch conditions.

Shahriari highlighted advanced dermatology treatments, clinical trial inclusivity, and key care strategies for complex skin conditions at Fall Clinical 2024.

Del Rosso reviews available and upcoming monoclonal antibodies, including nemolizumab, lebrikizumab, bimekizumab, and more.

Phase 3b study showed promise in clearing moderate PsO in sensitive areas for patients unresponsive to topical treatments.

Christopher Bunick, MD, PhD, presented the latest period 2 data at Fall Clinical 2024.

Catch up on coverage from the first day of the 2024 Fall Clinical Dermatology Conference in Las Vegas, Nevada.

Clinicians presented a panel-style session at Fall Clinical, touching on the drawbacks of topical steroid use and alternatives in AD patients.

Del Rosso reviews numerous new and upcoming topical therapeutics and indications including ruxolitinib, tapinarof, and more.

Among the many sessions to be held at the Fall Clinical Dermatology Conference in Las Vegas, Nevada, several Dermatology Times Editorial Advisory Board members are preparing to share their knowledge and insights.

The conference will feature presentations on a number of disease states, therapeutic options, and new clinical data.

Share with us the topics you want to learn more about at Fall Clinical.

The conference aimed at providing dermatology clinicians with the latest in the specialty begins today in Las Vegas, Nevada.

We want to know: Will you be attending the conference in Las Vegas later this week?

Aesthetic procedures for patients with skin of color necessitate a nuanced approach that prioritizes patient safety and optimal outcomes.

If you weren’t able to attend the 2023 Fall Clinical Dermatology Conference or want to review our latest coverage and interviews, our full recap has you covered.

Catch up on coverage from the final day of the 2023 Fall Clinical Dermatology Conference.

This study aimed to evaluate the association between the disease burden of psoriasis and the switching of systemic biologic therapies in patients with both psoriasis and psoriatic arthritis.

There is a lot of conversation drumming around the boxed warnings for newer JAK inhibitors, and fact versus fiction was discussed at Fall Clinical.

Susan Taylor, MD, walked Fall Clinical attendees through an in-depth hyperpigmentation session that included melasma and its mimickers.

Kirby presented at both Fall Clinical and the Inflammatory Disease Summit in Las Vegas.

Sandra Lee, MD, and other top acne experts took the stage to debate cases and treatments.

Primary and secondary melanoma prevention factors are necessary to reduce patients’ melanoma risk.

The latest CDC data shows an uptick in syphilis, which can lead to a rare form of alopecia or a presentation of psoriasis.

Catch up on coverage from the third day of the 2023 Fall Clinical Dermatology Conference.

Although still in its early stages, the program showcases the potential value of tangible interactions between dedicated navigators and patients in enhancing support and continuity of care.

Christopher Bunick, MD, PhD, reviews Cabtreo’s recent FDA approval and what the new triple-combination gel means for acne patients.

The pharmacokinetic profile of APG777, characterized by an extended half-life, increased exposure, and reduced clearance compared to lebrikizumab, is promising for patients with IL-13-driven diseases.

The goal of Arron et al’s study was to determine if the 40-GEP test could identify high-risk cSCC patients who would benefit from ART in controlling metastatic disease progression.